Positron emission tomography (PET) scanning using a tau tracer is a promising prognostic instrument for cognitive decline in the preclinical and prodromal stages of Alzheimer’s disease (AD).
Why this matters
Predicting the rate of cognitive decline in patients with AD is challenging, but critically important. Several biomarkers of neurodegeneration and AD pathology are now available, but our ability to provide an accurate prognosis for patients with AD remains limited.
Tau PET tracers are highly useful in distinguishing AD from other non-AD neurodegenerative conditions. However, it has also been suggested that elevated tau per baseline PET may be associated with more rapid cognitive decline and could be an indicator of AD prognosis.